update:Oct.28th 'MRNA' closed at $1.04. Where are the friendly research firms, their expert analysts, high target prices of $4.00 now? Besides the poor ratings, lack of interest in the stock, poor earnings, where will 'MRNA' attain the monies needed to get through all of 2010? This is the biggest question shareholders want to know about, not the speech they will hear from the qtly report Nov.12th or what the CEO has to say at the BMO conference which always sounds like peaches & cream. FOR ONCE CAN SHAREHOLDERS KNOW THE REAL DEAL? OBVIOUSLY AS I SO STATED A MONTH AGO THAT THE STOCK WAS HEADING BACK TO UNDER $1 DOLLAR AGAIN, AND WE ARE ALMOST THERE, SO NEXT WILL BE A NASDAQ LETTER AGAIN FOR COMPLIANCE BECAUSE NOTHING WILL BE HAPPENING TO THIS STOCK THE REST OF THE YEAR. OF COURSE THIS IS MY OPINION, BUT MY OPINIONS SINCE 2007 HAVE ALL COME TO FRUITION TO DATE.
$1.04 (10/28/09)
